Boulder, Colo. – July 12, 2018 – Inscripta, a leading gene-editing technology company, today announced two significant milestones. First, the USPTO granted Inscripta its first patent covering systems using MAD7, the company’s first free CRISPR enzyme, as well as patent coverage for systems using another MADzyme, MAD2. Second, Inscripta released new data run by external partners showing MAD7 can edit mammalian cells.
Boulder, Colo. – February 28, 2018 – Inscripta, a leading gene-editing technology company, today announced that it has closed a $55.5 million Series C funding round led by Mérieux Développement and Paladin Capital Group.
Boulder, Colo. – February 6, 2018 – In a significant move forward in developing gene-editing tools, Inscripta – a gene-editing technology company – today announced leading protein-engineering expert Richard Fox, Ph.D., has joined as executive director of data science.
Boulder, Colo. – December 13, 2017 – In a huge step forward for innovation in the cutting-edge field of CRISPR gene-editing, Inscripta – a gene-editing technology company – announced today that it is releasing one of its own, unique CRISPR enzymes, which will be free for all researchers to use.
Boulder, CO – May 09, 2017 – Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first CEO and former COO of Illumina and a well-known genomics industry entrepreneur, will become Chairman of Muse bio’s Board of Directors.
Boulder CO – February 28, 2017 – Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.
Boulder, CO – December 15, 2016 – Muse bio today announced the publication of a paper in Nature Biotechnology describing, for the first time, its foundational technology platform that enables rational engineering of the whole genome with single-nucleotide precision.
Boulder, CO – December 7, 2016 – Muse bio, a privately-held company leading the development of next-generation genome engineering technologies, today announced that Dr. Kevin Ness has been appointed Chief Executive Officer and member of the Board of Directors.